We explored the relationship between CD5, CD117, EZH2, POU2F3, MTAP, and BAP1 immunoreactivity and the overall survival (OS) and progression-free survival (PFS) of patients with thymic carcinoma, using a cohort with diverse histologic subtypes. This evidence concerns the gene EZH2 and thymic carcinoma.